Contact
searchSearch
HMP Global
Login

News

News
Nivolumab Plus Chemotherapy Maintains Survival Advantage in Gastroesophageal Adenocarcinoma
02/12/2026
Stephanie Holland
Long-term follow-up results from the phase 3 CheckMate 649 trial demonstrate that adding nivolumab to chemotherapy continues to prolong survival in previously untreated patients with non-HER2-positive, unresectable or metastatic...
Long-term follow-up results from the phase 3 CheckMate 649 trial demonstrate that adding nivolumab to chemotherapy continues to prolong survival in previously untreated patients with non-HER2-positive, unresectable or metastatic...
Long-term follow-up results from...
02/12/2026
Oncology
News
Anbenitamab Plus Chemotherapy After Trastuzumab Failure in HER2-Positive G/GEJ Cancer
01/21/2026
Stephanie Holland
Results from a multicenter, phase 3 trial demonstrated that anbenitamab plus chemotherapy improved survival compared with placebo plus chemotherapy among previously treated patients with HER2-positive gastric or gastroesophageal junction...
Results from a multicenter, phase 3 trial demonstrated that anbenitamab plus chemotherapy improved survival compared with placebo plus chemotherapy among previously treated patients with HER2-positive gastric or gastroesophageal junction...
Results from a multicenter,...
01/21/2026
Oncology
News
Addition of Tislelizumab to Neoadjuvant Chemoradiotherapy Shows Clinical Promise for Gastric/GEJ Cancer
01/13/2026
Stephanie Holland
Phase 2b results from the TERRIFIC study demonstrate that neoadjuvant tislelizumab plus chemoradiotherapy shows clinical promise for locally advanced gastric or gastroesophageal junction cancer.
Phase 2b results from the TERRIFIC study demonstrate that neoadjuvant tislelizumab plus chemoradiotherapy shows clinical promise for locally advanced gastric or gastroesophageal junction cancer.
Phase 2b results from the...
01/13/2026
Oncology
News
Addition of Tislelizumab to Neoadjuvant Chemoradiotherapy Shows Clinical Promise for Gastric/GEJ Cancer
01/13/2026
Stephanie Holland
Phase 2b results from the TERRIFIC study demonstrate that neoadjuvant tislelizumab plus chemoradiotherapy shows clinical promise for locally advanced gastric or gastroesophageal junction cancer.
Phase 2b results from the TERRIFIC study demonstrate that neoadjuvant tislelizumab plus chemoradiotherapy shows clinical promise for locally advanced gastric or gastroesophageal junction cancer.
Phase 2b results from the...
01/13/2026
Oncology
News
Zolbetuximab Plus mFOLFOX6 and Nivolumab Shows Promise for CLDN18.2-Positive Gastric and Gastroesophageal Junction Adenocarcinoma
01/08/2026
Stephanie Holland
Zolbetuximab plus mFLOFOX and nivolumab demonstrated clinical promise among HER2-negative patients with locally advanced unresectable or metastatic gastric or gastroesophageal junction adenocarcinoma with high CLDN18.2 expression, according...
Zolbetuximab plus mFLOFOX and nivolumab demonstrated clinical promise among HER2-negative patients with locally advanced unresectable or metastatic gastric or gastroesophageal junction adenocarcinoma with high CLDN18.2 expression, according...
Zolbetuximab plus mFLOFOX and...
01/08/2026
Oncology
News
Zolbetuximab Plus mFOLFOX6 and Nivolumab Shows Promise for CLDN18.2-Positive Gastric and Gastroesophageal Junction Adenocarcinoma
01/08/2026
Stephanie Holland
Zolbetuximab plus mFLOFOX and nivolumab demonstrated clinical promise among HER2-negative patients with locally advanced unresectable or metastatic gastric or gastroesophageal junction adenocarcinoma with high CLDN18.2 expression, according...
Zolbetuximab plus mFLOFOX and nivolumab demonstrated clinical promise among HER2-negative patients with locally advanced unresectable or metastatic gastric or gastroesophageal junction adenocarcinoma with high CLDN18.2 expression, according...
Zolbetuximab plus mFLOFOX and...
01/08/2026
Oncology
News
Frontline Zanidatamab-Based Treatment Demonstrates Promise for HER2-Positive Metastatic Gastroesophageal Adenocarcinoma
01/08/2026
Stephanie Holland
According to results from the phase 3 HERIZON-GEA-01 trial, zanidatamab-based treatment demonstrates a promising survival benefit among previously untreated patients with HER2-positive metastatic gastroesophageal adenocarcinoma.
According to results from the phase 3 HERIZON-GEA-01 trial, zanidatamab-based treatment demonstrates a promising survival benefit among previously untreated patients with HER2-positive metastatic gastroesophageal adenocarcinoma.
According to results from the...
01/08/2026
Oncology
News
Frontline Zanidatamab-Based Treatment Demonstrates Promise for HER2-Positive Metastatic Gastroesophageal Adenocarcinoma
01/08/2026
Stephanie Holland
According to results from the phase 3 HERIZON-GEA-01 trial, zanidatamab-based treatment demonstrates a promising survival benefit among previously untreated patients with HER2-positive metastatic gastroesophageal adenocarcinoma.
According to results from the phase 3 HERIZON-GEA-01 trial, zanidatamab-based treatment demonstrates a promising survival benefit among previously untreated patients with HER2-positive metastatic gastroesophageal adenocarcinoma.
According to results from the...
01/08/2026
Oncology
News
First-Line Capecitabine Plus Carboplatin Reduces Neurotoxicity Without Compromising Efficacy in Metastatic HER2-Negative Esophagogastric Adenocarcinoma
01/08/2026
Stephanie Holland
According to results from a multicenter phase 2 trial, first-line capecitabine plus carboplatin improved outcomes among previously untreated patients with metastatic or unresectable HER2-negative esophagogastric adenocarcinoma.
According to results from a multicenter phase 2 trial, first-line capecitabine plus carboplatin improved outcomes among previously untreated patients with metastatic or unresectable HER2-negative esophagogastric adenocarcinoma.
According to results from a...
01/08/2026
Oncology
News
First-Line Capecitabine Plus Carboplatin Reduces Neurotoxicity Without Compromising Efficacy in Metastatic HER2-Negative Esophagogastric Adenocarcinoma
01/08/2026
Stephanie Holland
According to results from a multicenter phase 2 trial, first-line capecitabine plus carboplatin improved outcomes among previously untreated patients with metastatic or unresectable HER2-negative esophagogastric adenocarcinoma.
According to results from a multicenter phase 2 trial, first-line capecitabine plus carboplatin improved outcomes among previously untreated patients with metastatic or unresectable HER2-negative esophagogastric adenocarcinoma.
According to results from a...
01/08/2026
Oncology

Recent News

FDA Approval
FDA Approves Nivolumab Plus Doxorubicin, Vinblastine, and Dacarbazine for Previously Untreated Patients With Advanced Classical Hodgkin Lymphoma
03/20/2026
Emily Estrada
Based on results from the SWOG 1826 trial, the FDA has approved nivolumab plus doxorubicin, vinblastine, and dacarbazine for previously untreated patients with advanced classical Hodgkin lymphoma.
Based on results from the SWOG 1826 trial, the FDA has approved nivolumab plus doxorubicin, vinblastine, and dacarbazine for previously untreated patients with advanced classical Hodgkin lymphoma.
Based on results from the SWOG...
03/20/2026
Oncology
News
Botensilimab Plus Balstilimab Demonstrates Promise in Refractory Metastatic Colorectal Cancer
03/18/2026
Emily Estrada
According to a comparative analysis of clinical trial data, botensilimab plus balstilimab provided a promising overall survival benefit in refractory MSS metastatic colorectal cancer.
According to a comparative analysis of clinical trial data, botensilimab plus balstilimab provided a promising overall survival benefit in refractory MSS metastatic colorectal cancer.
According to a comparative...
03/18/2026
Oncology
News
Belzutifan Plus Lenvatinib Improves PFS in Advanced Clear Cell Renal Cell Carcinoma
03/11/2026
Stephanie Holland
Interim results from the phase 3 LITESPARK-011 trial demonstrate that belzutifan plus lenvatinib significantly improved progression-free survival compared with cabozantinib among previously treated patients with advanced clear cell renal cell...
Interim results from the phase 3 LITESPARK-011 trial demonstrate that belzutifan plus lenvatinib significantly improved progression-free survival compared with cabozantinib among previously treated patients with advanced clear cell renal cell...
Interim results from the phase 3...
03/11/2026
Oncology
News
Mezigdomide Plus Carfilzomib and Dexamethasone Improves PFS in R/R Multiple Myeloma
03/11/2026
Stephanie Holland
Interim results from the phase 3 SUCCESSOR-2 trial demonstrate that mezigdomide plus carfilzomib and dexamethasone significantly improved PFS in patients with relapsed/refractory multiple myeloma versus carfilzomib and dexamethasone alone.
Interim results from the phase 3 SUCCESSOR-2 trial demonstrate that mezigdomide plus carfilzomib and dexamethasone significantly improved PFS in patients with relapsed/refractory multiple myeloma versus carfilzomib and dexamethasone alone.
Interim results from the phase 3...
03/11/2026
Oncology
News
FDA Approves Piflufolastat F 18 Injection for the Detection of PSMA-Positivity Among Patients With Prostate Cancer
03/11/2026
Stephanie Holland
Based on results from the OSPREY and CONDOR trials, the FDA has approved piflufolastat F 18 injection for the detection of PSMA-positive lesions in patients with prostate cancer.
Based on results from the OSPREY and CONDOR trials, the FDA has approved piflufolastat F 18 injection for the detection of PSMA-positive lesions in patients with prostate cancer.
Based on results from the OSPREY...
03/11/2026
Radiopharmaceutical Education Institute
FDA Alerts
Ipsen Voluntarily Withdraws Tazemetostat Following Updated Safety Findings from the SYMPHONY-1 Trial
03/11/2026
Stephanie Holland
Based on emerging safety data from the ongoing SYMPHONY-1 trial, Ipsen has voluntarily withdrawn tazemetostat across all approved indications.
Based on emerging safety data from the ongoing SYMPHONY-1 trial, Ipsen has voluntarily withdrawn tazemetostat across all approved indications.
Based on emerging safety data...
03/11/2026
Oncology
News
Pimicotinib Maintains Favorable Safety Profile in Tenosynovial Giant Cell Tumor
03/11/2026
Stephanie Holland
Updated safety results from the phase 3 MANEUVER trial demonstrate that pimicotinib was associated with manageable and largely reversible adverse events among patients with symptomatic, unresectable tenosynovial giant cell tumor.
Updated safety results from the phase 3 MANEUVER trial demonstrate that pimicotinib was associated with manageable and largely reversible adverse events among patients with symptomatic, unresectable tenosynovial giant cell tumor.
Updated safety results from the...
03/11/2026
Oncology
News
Cemiplimab Improves Disease-Free Survival in High-Risk Cutaneous Squamous Cell Carcinoma
03/05/2026
Stephanie Holland
Results from the phase 3 C-POST trial demonstrated that adjuvant cemiplimab significantly improved disease-free survival compared with placebo among patients with high-risk cSCC.
Results from the phase 3 C-POST trial demonstrated that adjuvant cemiplimab significantly improved disease-free survival compared with placebo among patients with high-risk cSCC.
Results from the phase 3 C-POST...
03/05/2026
Oncology
FDA Approval
FDA Approves Teclistamab Plus Daratumumab Hyaluronidase for Relapsed or Refractory Multiple Myeloma
03/05/2026
Emily Estrada
Based on results from the phase 3 MajesTEC-3 trial, the FDA approved teclistamab plus daratumumab hyaluronidase for previously treated patients with relapsed or refractory multiple myeloma.
Based on results from the phase 3 MajesTEC-3 trial, the FDA approved teclistamab plus daratumumab hyaluronidase for previously treated patients with relapsed or refractory multiple myeloma.
Based on results from the phase...
03/05/2026
Oncology
News
Tokyo-172 BCG is Noninferior to TICE BCG in High-Risk Non-Muscle Invasive Bladder Cancer
03/04/2026
Emily Estrada
Results from the SWOG S162 study demonstrated that Tokyo-172 BCG was noninferior to TICE BCG in patients with high-risk non-muscle invasive bladder cancer.
Results from the SWOG S162 study demonstrated that Tokyo-172 BCG was noninferior to TICE BCG in patients with high-risk non-muscle invasive bladder cancer.
Results from the SWOG S162 study...
03/04/2026
Oncology

HMP Global Products

Events

HMP Education Logo
HMP Omnimedia Logo
HMP Europe Logo
© 2026 HMP Global. All Rights Reserved.
Cookie Policy Privacy Policy Terms of Use